The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

CORONARY INTERVENTIONS

Intravascular ultrasound findings of the Fantom sirolimus-eluting bioresorbable scaffold at six- and nine-month follow-up: the FANTOM II study

EuroIntervention 2018;14:e1215-e1223 published online September 2018 published online e-edition December 2018. DOI: 10.4244/EIJ-D-18-00491

1. Department of Cardiology, Erasmus MC, Rotterdam, the Netherlands; 2. Department of Cardiology, University Hospital, Kraków, Poland; 3. Cardiac Research GmbH, St.-Johannes-Hospital, Dortmund, Germany; 4. Dante Pazzanese Cardiology Institute, São Paulo, Brazil; 5. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; 6. Department of Cardiology, St Vincent’s Hospital, Sydney, Australia; 7. 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland; 8. Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen, Denmark; 9. Department of Cardiology, St. Raphael Hospital, Kraków, Poland; 10. Department of Cardiology, Academic Medical Center, Amsterdam, the Netherlands; 11. Clinical Core Laboratory, Cardialysis, Rotterdam, the Netherlands

Aims: FANTOM II is a prospective multicentre trial assessing the safety and efficacy of the Fantom sirolimus-eluting bioresorbable coronary scaffold (BRS). The present substudy focuses on the six- and nine-month IVUS findings.

Methods and results: A total of 240 patients with de novo coronary artery lesions presenting with stable or unstable disease were included in two sequential cohorts (cohort A [n=117] and cohort B [n=123]) in which angiographic follow-up was performed at either six or nine months, respectively. Matched IVUS data were available for 35 paired cases in cohort A and 26 paired cases in cohort B. At six months, mean and minimum scaffold area (SA) decreased from 6.09±1.08 mm2 to 5.88±1.07 mm2, p=0.009, and 5.27±0.99 mm2 to 5.05±0.99 mm2, p=0.01, respectively. At nine months, no significant change in mean scaffold and minimum scaffold area was observed (6.46±1.11 mm2 to 6.38±0.96 mm2; p=0.35, and 5.45±1.00 mm2 to 5.36±0.86 mm2; p=0.32, respectively). Neointimal hyperplasia area was low at both six (0.11±0.12 mm2) and nine months (0.20±0.21 mm2), as was in-scaffold obstruction volume (1.94±2.25% at six months, and 3.40±4.11% at nine months).

Conclusions: The use of the Fantom BRS in stable coronary artery disease was associated with low rates of neointimal hyperplasia volume and in-scaffold volume obstruction at both six and nine months.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)